In order to understand the Chaperonze® results, it is important to understand two key biomarkers that we use to measure the success of the treatment. The best way to measure the results of Chaperonze® is to have a blood test prior to each course , measuring the markers covered below. Then have blood tests after each 4 month course.
HSP70 is our key biomarker for the Chaperone Protein Axis, (CPA).
As we get older our Axis starts slowing down inside the cell, which leads to protein accumulation and alteration in translation of mRNA to functional proteins. This, in turn, slows the cell’s metabolism and has a significant effect on our body’s ability to function and fight disease states.
The cells become slightly ‘porous’ and HSP70 ‘leaks’ out into our bloodstream. In short, as we age, our circulating HSP70 increases as our cells become impaired.
As long as there is no ongoing clinical disease, Chaperonze® can help create cell stabilisation. CPA application with Chaperonze® increase HSP70 production inside the cell, stabilising the cell, repairing the cell, and leading to a decrease in circulating HSP70, (HSP70 in the bloodstream).
We use IGF-1 as a key biomarker of the Somatotropic (Growth Hormone) Axis. Through our research, and clinical studies, we have found evidence, which leads us to firmly believe, that, overall, as your cellular health increases, so too will your key hormonal function.
We know that IGF-1 decreases with age and our research and studies have also led us to believe that this is due to an overall decrease in cellular function. The IGF-1 is somewhat inhibited from being translated in the cell and so decreases the physiologic function.